Vera Therapeutics/VERA

$47.80

3.12%
-
1D1W1MYTD1YMAX

About Vera Therapeutics

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants.

Ticker

VERA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Marshall Fordyce

Employees

49

Headquarters

Brisbane, United States
Website
veratx.com

VERA Metrics

BasicAdvanced
$2.49B
Market cap
-
P/E ratio
-$2.90
EPS
-
Beta
-
Dividend rate

What the Analysts think about VERA

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 8 analysts.
34.62% downside
High $50.00
Low $21.00
$47.80
Current price
$31.25
Average price target

VERA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-20.1M
-0%
Profit margin
0%
-

VERA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.62%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.18
-$0.80
-$0.46
-$0.45
-
Expected
-$0.90
-$0.60
-$0.69
-$0.53
-$0.51
Surprise
30.63%
32.45%
-33.65%
-15.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Vera Therapeutics stock

Buy or sell Vera Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing